| 发明名称 |
TARGETING OF INTERLEUKIN-1 AND -18 SIGNALING IN TREATMENT OF SEPTIC SHOCK |
| 摘要 |
The present invention relates to the inactivation of interleukin-1 and interleukin-18 signaling in treatment of inflammation and septic shock. More specifically, it relates to a sequential or simultaneous application of both an interleukin-1 receptor antagonist and an interleukin-18 antibody. In one preferred embodiment, a combination treatment of an IL-1 receptor antagonist and an IL-18 antibody is used. |
| 申请公布号 |
US2016331837(A1) |
申请公布日期 |
2016.11.17 |
| 申请号 |
US201515111374 |
申请日期 |
2015.01.15 |
| 申请人 |
VIB VZW ;UNIVERSITEIT GENT |
发明人 |
Vandenabeele Peter;Cauwels Anje;Vandenberghe Tom |
| 分类号 |
A61K39/395;C07K16/24;C07K16/28;A61K38/20 |
主分类号 |
A61K39/395 |
| 代理机构 |
|
代理人 |
|
| 主权项 |
1. A method of treating sepsis comprising administering an interleukin-1 receptor antagonist and an interleukin-18 antibody to a subject in need thereof. |
| 地址 |
Gent BE |
